The FDA has granted fast track designation to CFI-402257, a novel therapy for treating adult patients with ER-positive/HER2-negative advanced breast cancer, especially after disease progression on prior CDK4/6 inhibitors and endocrine therapy. This designation is based on early signs of durable activity and a manageable safety profile of CFI-402257, both as a monotherapy and in combination with fulvestrant.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.